Innovent Biologics Inc. has announced a strategic collaboration with Eli Lilly and Company to jointly develop novel medicines in the fields of oncology and immunology. This marks the seventh partnership between the two companies and aims to accelerate global development of Innovent's innovative pipeline. Under the agreement, Innovent will lead early-stage development through Phase 2 clinical trials in China, while Lilly will have exclusive rights to develop and commercialize these medicines outside Greater China. Innovent will receive a $350 million upfront payment and could earn up to $8.5 billion in milestone payments, as well as tiered royalties on sales outside Greater China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN83156) on February 08, 2026, and is solely responsible for the information contained therein.